Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma
SHANGHAI, April 1, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral small-molecule FGFR4 inhibitor irpagratinib...
Prepare for a Healthier Holiday Season with Wellness Tips from VARON Oxygen Concentrators
MANILA, Philippines , Dec. 19, 2025 /PRNewswire/ -- As the holiday season begins to unfold in the Philippines, families are starting to plan gatherings, reunions, and early celebrations. For households with elderly relatives or loved ones managing...
Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC
SHANGHAI, June 16, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of irpagratinib, a self-developed and highly-selective small molecule FGFR4...